Search Results - "HOHNEKER, J. A"

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase by Baker, S D, Khor, S P, Adjei, A A, Doucette, M, Spector, T, Donehower, R C, Grochow, L B, Sartorius, S E, Noe, D A, Hohneker, J A, Rowinsky, E K

“…To study the absolute bioavailability and pharmacokinetics of an oral solution of fluorouracil (5-FU) in patients treated with 776C85, an oral inactivator of…”
Get more information

Allopurinol: Intravenous Use for Prevention and Treatment of Hyperuricemia by SMALLEY, R. V, GUASPARI, A, HAASE-STATZ, S, ANDERSON, S. A, CEDERBERG, D, HOHNEKER, J. A

“…To tabulate data obtained over a 21-year period to determine the efficacy and safety of an intravenous (IV) allopurinol preparation. IV allopurinol was…”
Get full text

Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator Eniluracil by BAKER, S. D, DIASIO, R. B, ROWINSKY, E. K, O'REILLY, S, LUCAS, V. S, SOO PEANG KHOR, SARTORIUS, S. E, DONEHOWER, R. C, GROCHOW, L. B, SPECTOR, T, HOHNEKER, J. A

“…To determine the maximum-tolerated dose (MTD), toxicities, and pharmacokinetics of oral fluorouracil (5-FU) administered twice daily in combination with oral…”
Get full text

A summary of vinorelbine (Navelbine) safety data from North American clinical trials by Hohneker, J A

“…Extensive clinical experience has been obtained with the antineoplastic agent vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre…”
Get more information

Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer by Vokes, E E, Rosenberg, R K, Jahanzeb, M, Craig, J B, Gralla, R J, Belani, C P, Jones, S E, Bigley, J W, Hohneker, J A

“…We initiated a large multicenter phase II trial in stage IV non-small-cell lung cancer (NSCLC) to evaluate the activity and safety of an oral gelatin-based…”
Get more information

Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors by Rowinsky, E K, Noe, D A, Trump, D L, Winer, E P, Lucas, V S, Wargin, W A, Hohneker, J A, Lubejko, B, Sartorius, S E, Ettinger, D S

“…The feasibility of administering vinorelbine (Navelbine, Burroughs Wellcome Co, Research Triangle Park, NC), a semisynthetic vinca alkaloid with broad…”
Get more information

Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer by HAVLIN, K. A, RAMIREZ, M. J, LEGLER, C. M, HARRIS, L. N, MATULONIS, U. A, HOHNEKER, J. A, HAYES, D. F, WINER, E. P

“…Vinorelbine (Navelbine) is a semi-synthetic vinca alkaloid with documented activity in breast cancer. The major dose-limiting toxicity (DLT) when given weekly…”
Get full text

Safety and Pain Palliation of Zoledronic Acid in Patients with Breast Cancer, Prostate Cancer, or Multiple Myeloma Who Previously Received Bisphosphonate Therapy by Vogel, Charles L., Yanagihara, Ronald H., Wood, Albert J., Schnell, Frederick M., Henderson, Charles, Kaplan, Barry H., Purdy, Malcolm H., Orlowski, Richard, Decker, Jodi L., Lacerna, Leo, Hohneker, John A.

“…An open‐label study conducted in community centers assessed the safety of zoledronic acid 4 mg intravenously over 15 minutes every 3–4 weeks as treatment of…”
Get full text

Phase II evaluation of the AMAP, 773U82 mesylate, in pancreatic cancer by TRUMP, D. L, HATHORN, J. A, GROCHOW, L. B, SPRIGGS, D, EBLE, M. L, HOHNEKER, J. A

“…Pancreatic cancer is the fifth leading cause in cancer related death among adults in the United States. Thirty-thousand new cases of pancreatic cancer are…”
Get full text

Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion by SCHILSKY, R. L, RATAIN, M. J, JANISCH, L, VOGELZANG, N. J, SOL LUCAS, V, RAVITCH, J, HOHNEKER, J. A, CLENDENINN, N. J, TUTTLE, R. L

“…502U83 is an arylmethylaminopropanediol that displays significant antitumor activity in a number of murine and human tumor-model systems. In the present phase…”
Get full text

A Phase I and Pharmacokinetic Study of 1843U89, a Noncompetitive Inhibitor of Thymidylate Synthase, in Patients with Advanced Solid Malignancies by SCHWARTZ, Garry, JOHNSON, Thomas R, GOETZ, Andrew, BURRIS, Howard, SMETZER, Leslie, LAMPKIN, Thomas, SAILSTAD, Jeffrey, HOHNEKER, John A, VON HOFF, Daniel D, ROWINSKY, Eric K

“…This study was performed to assess the feasibility of administering 1843U89, a potent, noncompetitive inhibitor of thymidylate synthase that does not require…”
Get full text

Clinical development of eniluracil: current status by Hohneker, J A

“…Eniluracil is a potent inactivator of dihydropyrimidine dehydrogenase (DPD), which is the first enzyme in the degradative pathway of systemically administered…”
Get more information

The effects of food and divided dosing on the bioavailability of oral vinorelbine by Rowinsky, E K, Lucas, V S, Hsieh, A L, Wargin, W A, Hohneker, J A, Lubejko, B, Sartorius, S E, Donehower, R C

“…The effects of food and divided dosing on the bioavailability of a liquid-filled gelatin capsule formulation of vinorelbine (Navelbine), a semisynthetic vinca…”
Get full text

The effects of food and divised dosing on the bioavailability of oral vinorelbine by ROWINSKY, E. K, SOL LUCAS, V, HSIEH, A.-L. Y, WARGIN, W. A, HOHNEKER, J. A, LUBEJKO, B, SARTORIUS, S. E, DONCHOWER, R. C

Get full text

Important drug precaution for dental health professionals with patients being treated for cancer by Hohneker, John A, Bess, Alan L

Get more information

Phase I evaluation of 773U82-HCI in a two-hour infusion repeated daily for three days by BAILEY, H, KOHLER, P, TUTTLE, R, CARBONE, P. P, HOHNEKER, J. A, CLENDENINN, N. J, WILDING, G

Get full text

Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days by Bailey, H, Kohler, P, Tuttle, R, Carbone, P P, Hohneker, J A, Clendeninn, N J, Wilding, G

“…One of a novel series of compounds (AMAPS or arylmethylaminopropanediols), 773U82-HCl has shown significant antitumor activity in in vitro and in in vivo tumor…”
Get full text

Saponification of dimethyl cis-2,6-diphenyl-4-oxocyclohexane-1,1-dicarboxylate. A reinvestigation by Rowland, Alex T, Hohneker, John A, McDaniel, Keith F, Moore, David S

Get full text